Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vivesto AB ( (SE:VIVE) ) just unveiled an announcement.
Vivesto AB held a live-streamed business update to discuss recent advancements in their oncology pipeline, highlighting positive interim results from the Paccal Vet clinical study in dogs and promising preclinical data for Cantrixil in hematological cancers. The update, featuring insights from both internal and external experts, outlined development plans and the commercial potential of these programs, emphasizing their impact on addressing unmet medical needs in both human and veterinary oncology.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on oncology, aiming to provide new treatment options for hard-to-treat cancers with significant medical needs and market potential. Its project portfolio includes Cantrixil for blood cancer and Paccal Vet, a veterinary oncology program under evaluation in clinical trials for dogs and cats.
YTD Price Performance: -50.34%
Average Trading Volume: 681,253
Technical Sentiment Signal: Sell
Current Market Cap: SEK77.48M
Find detailed analytics on VIVE stock on TipRanks’ Stock Analysis page.